Vaishali Pharma Limited has informed the Exchange about General Updates
VAISHALI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vaishali Pharma Limited has filed an annual disclosure under SEBI Regulation 31(4), which requires promoters to disclose any encumbrance (pledge/charge) created on their shares. The disclosure, submitted by Promoter and Chairman cum Managing Director Atul Arvindbhai Vasani on behalf of the Promoter and Promoter Group, confirms that no encumbrances were created over the company's shares during the Financial Year ended 31st March, 2026. This is a routine compliance filing for the FY 2025-26. The company secretary Vishwa Mekhia also confirmed receipt of this disclosure on the same date.
Positive for shareholders as it confirms that the promoter group has not pledged their shares, indicating stable ownership and no potential dilution risk from encumbrances.